Dash, Srikanta Aydin, Yucel Widmer, Kyle E Nayak, Leela
Published in
Journal of hepatocellular carcinoma
Hepatitis C virus (HCV) infection is the major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC). The mechanisms of HCC initiation, growth, and metastasis appear to be highly complex due to the decade-long interactions between the virus, immune system, and overlapping bystander effects of host metabolic liver disease. The lack of a...
Njiomegnie, Gaitan Fabrice Read, Scott A. Fewings, Nicole George, Jacob McKay, Fiona Ahlenstiel, Golo
Published in
Journal of Clinical Medicine
Hepatitis C virus (HCV) infection develops into chronic hepatitis in over two-thirds of acute infections. While current treatments with direct-acting antivirals (DAAs) achieve HCV eradication in >95% of cases, no vaccine is available and re-infection can readily occur. Natural killer (NK) cells represent a key cellular component of the innate immun...
Schulz, Thomas R Kanhutu, Kudzai Sasadeusz, Joseph Watkinson, Sally Biggs, Beverley-Ann
Published in
Journal of telemedicine and telecare
Bajis, Sahar Grebely, Jason Hajarizadeh, Behzad Applegate, Tanya Marshall, Alison D Ellen Harrod, Mary Byrne, Jude Bath, Nicky Read, Phillip Edwards, Michael
...
Published in
Journal of viral hepatitis
Gaps in hepatitis C virus (HCV) testing, diagnosis, liver disease assessment and treatment uptake among people who inject drugs (PWID) persist. We aimed to describe the cascade of HCV care among PWID in Australia, prior to and following unrestricted access to direct-acting antiviral (DAA) treatment. Participants enrolled in an observational cohort ...
Cacciola, Irene Borgia, Francesco Filomia, Roberto Pitrone, Concetta Franzè, Maria Stella Alibrandi, Angela Squadrito, Giovanni Guarneri, Claudio Papaianni, Valeria Cannavò, Serafinella Patrizia
...
Published in
Journal of viral hepatitis
Apart from chronic liver disease, hepatitis C virus (HCV) may be responsible for several extra-hepatic manifestations. Its involvement in psoriasis development is still controversial. The aim of this study was to evaluate the possible effect of anti-HCV direct-acting antiviral (DAA) treatment on cutaneous psoriasis. Thirty-seven consecutive HCV pat...
Ogawa, Eiichi Nomura, Hideyuki Nakamuta, Makoto Kawano, Akira Dohmen, Kazufumi Kajiwara, Eiji Satoh, Takeaki Koyanagi, Toshimasa Takahashi, Kazuhiro Ooho, Aritsune
...
Published in
Hepatology research : the official journal of the Japan Society of Hepatology
Hepatitis C virus genotype 2 is common in East Asia, sub-Saharan Africa, and Latin America. However, many countries in these areas lag behind other areas of the world in government approval for new direct-acting antivirals. The aim of this study was to evaluate the treatment outcome of ledipasvir/sofosbuvir (LDV/SOF) for patients with chronic hepat...
Fuchs, Michael Monto, Alexander Bräu, Norbert Charafeddine, Mariem Schmidt, Warren Kozal, Michael Naggie, Susanna Cheung, Ramsey Schnell, Gretja Yu, Yao
...
Published in
Journal of medical virology
Hepatitis C virus (HCV) infections are more common among US veterans receiving care through Veterans Affairs (VA) Medical Centers than among the general population. Historically, HCV therapies had lower efficacy rates in VA patients, possibly due to common comorbidities such as psychiatric disorders and substance abuse. The direct-acting antivirals...
Berliba, Elina Bogus, Maxim Vanhoutte, Frédéric Berghmans, Pieter-Jan Good, Steven S. Moussa, Adel Pietropaolo, Keith Murphy, Robert L. Zhou, Xiao-Jian Sommadossi, Jean-Pierre
...
Published in
Antimicrobial Agents and Chemotherapy
AT-527 is a novel modified guanosine nucleotide prodrug inhibitor of the hepatitis C virus (HCV) NS5B polymerase, with increased in vitro antiviral activity compared to sofosbuvir and a highly differentiated favorable preclinical profile compared to other anti-HCV nucleoside/nucleotide analogs. This was a multiple-part clinical study where multiple...
Bhandari, Rajan Morey, Sarah Hamoodi, Abi Thompson, Craig Jones, Dee Hewett, Margaret Hunter, Ewan Taha, Yusri McPherson, Stuart
Published in
Journal of viral hepatitis
To achieve elimination of hepatitis C (HCV), a critical group to prioritise for diagnosis and treatment is the prison population, where HCV prevalence is high. A universal offer of blood-borne virus testing (UOBBVT) programme and a new treatment pathway were introduced to seven North East England (NEE) Prisons. Our aim was to assess: (a) the propor...
Comarmond, Cloé Lorin, Valérie Marques, Cindy Maciejewski-Duval, Anna Joher, Nizar Planchais, Cyril Touzot, Maxime Biard, Lucie Hieu, Thierry Quiniou, Valentin
...
Published in
Journal of hepatology
Hepatitis C virus (HCV) infection contributes to the development of autoimmune disorders such as cryoglobulinaemia vasculitis (CV). However, it remains unclear why only some individuals with HCV develop HCV-associated CV (HCV-CV). HCV-CV is characterized by the expansion of anergic CD19+CD27+CD21low/- atypical memory B cells (AtMs). Herein, we repo...
